Related Concept Videos
02:34Inhibition of Cdk Activity
5.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
01:07MAPK Signaling Cascades
6.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.9K
02:39Positive Regulator Molecules
6.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.0K
01:45Positive Regulator Molecules
116.8K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
116.8K
01:23Negative Regulator Molecules
37.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.2K
02:38Mitogens and the Cell Cycle
7.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Why promising ATMPs fail to reach patients: a qualitative stakeholder-informed analysis of cell therapy access in Europe.
Journal of translational medicine·2026
Same author
PPARα deficiency causes skin dysbiosis and triggers innate immunity in keratinocytes.
Cell death & disease·2026
Same author
Make or break - PEDS1 and AGMO orchestrate ether lipid homeostasis in human adipocytes and are associated with blood lipid profiles.
Journal of translational medicine·2026
Related Experiment Video
Updated: Nov 7, 2025
12:02
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
27.9K
Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57Kip2.
Michael Keith Kullmann1, Fragka Pegka1, Christian Ploner2
1Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Frontiers in Cell and Developmental Biology
|April 30, 2021
Summary
The cell cycle inhibitor p57 (also known as CDKN1C) activates the transcription factor c-Jun, potentially promoting tumor growth. This occurs by p57 interfering with c-Jun repressors and activators, independent of its cell cycle inhibition role.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- p57 (CDKN1C) is a cell cycle inhibitor and tumor suppressor, known to inhibit cyclin-dependent kinase (CDK) complexes.
- Mutations in p57 are linked to human overgrowth disorders, and it is implicated in processes beyond cell cycle control, including apoptosis and transcription.
- The transcription factor Activator Protein-1 (AP-1), a heterodimer often composed of c-Jun and c-Fos, regulates gene expression involved in cell proliferation, differentiation, and survival.
Purpose of the Study:
- To investigate the novel role of p57 in regulating AP-1 promoter activity, specifically focusing on its interaction with c-Jun.
- To elucidate the mechanism by which p57 influences c-Jun transactivation activity.
- To determine the functional domains of p57 involved in c-Jun activation and its potential implications in cancer.
Main Methods:
- Reporter gene assays to measure AP-1 promoter activity.
- Co-immunoprecipitation to detect endogenous p57/c-Jun complexes.
- Analysis of p57 deletion mutants (N- and C-terminal domains) to assess their role in c-Jun activation.
- Assays to investigate p57's effect on c-Jun phosphorylation and its interaction with c-Jun repressors (HDAC1, HDAC3).
Main Results:
- p57 significantly stimulates AP-1 promoter activity, primarily through enhanced transactivation by c-Jun, but not c-Fos.
- Endogenous p57 and c-Jun form complexes within cells, confirmed by co-immunoprecipitation.
- p57 activates c-Jun by interfering with repressors (like HDAC1/3 via the N-terminus) and potentially activators (via the C-terminus), rather than by altering c-Jun phosphorylation.
- The N-terminus of p57 binds to c-Jun repressors HDAC1 and HDAC3, while the C-terminus appears to interact with c-Jun activators.
Conclusions:
- p57 acts as a potent activator of c-Jun-mediated transcription, suggesting a novel role beyond cell cycle inhibition.
- The distinct N- and C-terminal domains of p57 mediate this activation through differential interactions with c-Jun repressors and activators.
- These findings propose that p57 may possess tumor-promoting functions by activating the proto-oncoprotein c-Jun, potentially through its integration into nuclear remodeling complexes.